Countries like South Korea, Singapore, and others in Asia are making strides in enhancing their bio-manufacturing capabilities. The collective effort made by the respective countries helps to position Asia as a key player in the global biopharma industry towards fostering innovation, international collaborations and investments, as well as improving the regulatory environment. According to Market Data Forecast, the Asia Pacific biopharmaceuticals market was valued at $44.3 billion in 2023 and is expected to be worth $78.69 billion by 2029 with a CAGR of 10.05 per cent from 2024 to 2029.
“Asia-Pacific has emerged as a dynamic and influential region in the global biopharma industry in recent years and this transformation is driven by a confluence of factors, from rapid economic growth and significant government investments to a highly skilled workforce and a supportive regulatory environment,” said Chua Keng Hock, Senior Vice President of Process Solutions, Asia Pacific, Life Science Business of Merck.
The support of the local government and investment are pivotal in driving the growth of the biopharma sector in Asia. “The local governments in Asia have made substantial investments in the biopharma sector, focusing on building infrastructure and creating life science hubs to foster collaboration and innovation. For example, South Korea's ‘BioHealth Industry Promotion Plan’ aims to enhance the country's biotechnology capabilities through initiatives like the National Synthetic Biology Initiative, which seeks to transition 30 per cent of the manufacturing industry to the bio-industry within a decade. Similarly, Singapore has built the Biopolis, a research and development hub, and Tuas Biomedical Park, a purpose-built estate for pharmaceutical and medical technology companies,” said Chua Keng Hock.
Esta historia es de la edición October 2024 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición October 2024 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Shimadzu launches operations in Mexico
Japan's Shimadzu Corporation has established a subsidiary in Mexico and has begun its activities.
Agilent unveils Biopharma CDx Services Lab to accelerate precision medicine
Agilent Technologies Inc., has announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, US following receipt of California State clinical laboratory license and Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance.
MilliporeSigma launches single-use reactor to accelerate ADCs manufacturing
MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has launched the first single-use reactor specifically designed to manufacture antibody drug conjugates (ADCs). ADCs are a rapidly emerging class of therapeutic agents that can target and selectively kill tumour cells, while protecting healthy ones.
Scopio Labs & Beckman Coulter to distribute digital bone marrow imaging and analysis app
US-based Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company based in Israel that develops digital cell morphology workflow solutions, have jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow Aspirate (FF-BMA) Application.
Hong Kong develops next-gen wearable continuous glucose monitoring system
An interdisciplinary research team, including the Faculty of Engineering and Li Ka Shing Faculty of Medicine at The University of Hong Kong (HKU), Zhejiang University, and Guangzhou Medical University, in China, has developed a groundbreaking continuous glucose monitoring (CGM) system which represents a major advancement in wearable health technology and is set to revolutionise diabetes management.
Singapore elevates analysis of genomic data with breakthrough mathematical technique
A novel approach for analysing single-cell RNA sequencing (scRNA-seq) data has been unveiled by researchers at the National University of Singapore (NUS).
Vatroslav Mateljic steps in as General Manager of Takeda Canada
Takeda Canada Inc. has announced the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company.
Bio Duro-Sundia appoints Dr Armin Spura as CEO
BioDuro-Sundia, a leading Contract Research, Development, and Manufacturing Organisation (CRDMO) based in the US and China, has announced the appointment of Dr Armin Spura as its new Chief Executive Officer (CEO).
Singapore's Health Sciences Authority appoints Adj A/ Prof. Raymond Chua as CEO
Adjunct Associate Professor Raymond Chua Swee Boon has been appointed as Chief Executive Officer-Designate of the Health Sciences Authority (HSA), Singapore and will officially assume the Chief Executive Officer (CEO) role from December 13, 2024. Dr Mimi Choong May Ling, the current CEO of HSA, will retire from public service with effect from December 13, 2024.
Novotech appoints Dr Yooni Kim as Managing Director for APAC region
Novotech, the leading global biotech Contract Research Organisation (CRO), has announced the appointment of Dr Yooni Kim as a new Executive position of Managing Director for the Asia-Pacific (APAC) region. The establishment of the Managing Director APAC role is a significant step, aligning Novotech’s operations across key regions, including the United States, Europe, Mainland China, and APAC.